Short answer
Xenon Pharmaceuticals Inc. (XENE) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q1 2026 financial results announced for the three months ended March 31, 2026.
Xenon Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results announced for the three months ended March 31, 2026
- Detailed results and management commentary available in Exhibit 99.1
- Investor focus: cash position, operating expenses, pipeline progress, and development funding needs
Item 7.01 · Regulation FD Disclosure
- Expanded investor-information channels, including SEC filings, press releases, conferences, websites, and social media
- Social-media disclosures may contain material information relevant to investors
- Investors should monitor Xenon’s investor-relations website and listed social accounts for company updates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xenon Pharmaceuticals Inc. 8-K filings
Get the next XENE 8-K as it lands
Follow XENE for push alerts, or ask the research agent what this filing means.